- Home
- ANEB vs ITRM Comparison
ANEB vs ITRM Comparison
Compare ANEB & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- ITRM
- Stock Information
- Founded
- ANEB 2020
- ITRM 2015
- Country
- ANEB United States
- ITRM Ireland
- Employees
- ANEB N/A
- ITRM N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- ITRM Health Care
- Exchange
- ANEB Nasdaq
- ITRM Nasdaq
- Market Cap
- ANEB 39.0M
- ITRM 36.3M
- IPO Year
- ANEB 2021
- ITRM 2018
- Fundamental
- Price
- ANEB $1.06
- ITRM $0.97
- Analyst Decision
- ANEB Strong Buy
- ITRM Strong Buy
- Analyst Count
- ANEB 2
- ITRM 2
- Target Price
- ANEB $5.50
- ITRM $7.00
- AVG Volume (30 Days)
- ANEB 11.6K
- ITRM 628.6K
- Earning Date
- ANEB 05-13-2025
- ITRM 05-13-2025
- Dividend Yield
- ANEB N/A
- ITRM N/A
- EPS Growth
- ANEB N/A
- ITRM N/A
- EPS
- ANEB N/A
- ITRM N/A
- Revenue
- ANEB N/A
- ITRM N/A
- Revenue This Year
- ANEB N/A
- ITRM N/A
- Revenue Next Year
- ANEB N/A
- ITRM $108.39
- P/E Ratio
- ANEB N/A
- ITRM N/A
- Revenue Growth
- ANEB N/A
- ITRM N/A
- 52 Week Low
- ANEB $0.80
- ITRM $0.81
- 52 Week High
- ANEB $3.08
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- ANEB 47.21
- ITRM 44.78
- Support Level
- ANEB $1.00
- ITRM $0.89
- Resistance Level
- ANEB $1.15
- ITRM $1.05
- Average True Range (ATR)
- ANEB 0.07
- ITRM 0.06
- MACD
- ANEB 0.01
- ITRM 0.01
- Stochastic Oscillator
- ANEB 44.49
- ITRM 49.94
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.